Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P030017/S399

Precision Spectra SCS Systems; Precision Novi SCS Systems; Precision Montage MRI SCS Systems; Spectra Wave Writer SCS Sy

Boston Scientific Corp · Decision date Sep 22, 2026

MEDTECHLEDGER EXPLANATIONP030017/S399

What did the FDA approve?

On 2026-09-22, FDA recorded an approval decision (APPR) for PMA supplement P030017/S399 from Boston Scientific Corp. The supplement is filed under the real-time process with the stated reason of a change to design, components, specifications or material. The recorded statement covers an alternate battery for the Charger devices SC-5312 and NM-5312, which the statement ties to Boston Scientific Spinal Cord Stimulation systems and Deep Brain Stimulation systems, respectively.

The supplement sits within the P030017 family, whose listed titles include the Precision Spectra, Precision Novi, Precision Montage MRI and Spectra Wave Writer SCS systems. The decision concerns the charger battery change, not a new approval of those systems. The product code is LGW, device category is a totally implanted spinal-cord stimulator for pain relief, and specialty is Neurology. The source gives no battery chemistry, performance data, or labeling changes, and no supporting documents are listed.

The record does not state whether the alternate battery affects charger compatibility, charging time, or service life, and no clinical or legal conclusion follows from the approval alone.

FDA approval order statement

approval for an alternate battery for the Charger devices SC-5312 and NM-5312 which are used with the Boston Scientific Spinal Cord Stimulation (SCS) systems and Deep Brain Stimulation (DBS) systems, respectively.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Neurology
Decision date
Sep 22, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P030017/S399
Regulatory pathway
PMA supplement
Product code
LGW
Decision code
APPR
Decision date
Sep 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, spinal-cord, totally implanted for pain relief.

Product code
LGW
FDA device class
3

For the original device and its historical approval scope, see PMA P030017. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P030017 · Original PMA

    PRECISION SPINAL CORD STIMULATION(SCS) SYSTEM

  2. P030017/S386 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  3. P030017/S389 · Related supplement

    WaveWriter Alpha Prime Spinal Cord Stimulation (SCS) Systems

  4. P030017/S390 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  5. P030017/S374 · Related supplement

    WaveWriter Alpha Spinal Cord Stimulator (SCS) Mixed Systems, M8 Adaptor

  6. P030017/S377 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  7. P030017/S391 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  8. P030017/S387 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems Introducer Hub Mold Change

  9. P030017/S394 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  10. P030017/S395 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  11. P030017/S392 · Related supplement

    Celestia Implantable Pulse Generator, Celestia External Trial Stimulator

  12. P030017/S393 · Related supplement

    Spinal Cord Stimulation (SCS)

  13. P030017/S397 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  14. P030017/S399 received

    Application receipt date recorded by FDA.

  15. P030017/S398 · Related supplement

    Precision Spinal Cord Stimulator (SCS) Systems

  16. P030017/S396 · Related supplement

    WaveWriter Alpha and WaveWriter Alpha Prime SCS Systems; Celestia and Celestia Prime SCS Systems

  17. P030017/S399 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P030017. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P030017

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA approvalApr 27, 2004FDA
Boston Scientific CorpPMA supplementSep 19, 2025FDA
Boston Scientific CorpPMA supplementDec 10, 2025FDA
Boston Scientific CorpPMA supplementDec 17, 2025FDA
Boston Scientific CorpPMA supplementDec 18, 2025FDA
Boston Scientific CorpPMA supplementJan 21, 2026FDA
Boston Scientific CorpPMA supplementJan 22, 2026FDA
Boston Scientific CorpPMA supplementFeb 11, 2026FDA
Boston Scientific CorpPMA supplementMay 13, 2026FDA
Boston Scientific CorpPMA supplementMay 18, 2026FDA
Boston Scientific CorpPMA supplementMay 21, 2026FDA
Boston Scientific CorpPMA supplementMay 28, 2026FDA
Boston Scientific CorpPMA supplementJul 10, 2026FDA
Boston Scientific CorpPMA supplementAug 10, 2026FDA
Boston Scientific CorpPMA supplementSep 9, 2026FDA

Explore the linked device profile

Other records with product code LGW

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
25155 Rye Canyon Loop, Valencia, CA, 91355

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records